April 2018
RCM Provides 
Advanced Computational Analysis 
to Assist Oncologists  in Delivering Personalized Cancer Treatments based on Genetic Markers

The research is clear:  Genetic markers of cancer, which are identified through an analysis of cancer DNA in a lab, can help Oncologists personalize treatments for improved outcomes and prolonged survival rates.
 
Here's how it works:   Oncologists receive critical data about specific genetic mutations. This allows them to deliver therapeutic strategies to overcome the patient's specific resistance mechanisms. Resistance mechanisms are common with cancer which can mutate over time.  
Intelligent Computational Systems enable -
more precise, personalized treatment strategies:
                               
RCM assists Oncologists with the selection of personalized combination treatment options for their patients.
 
·      The process begins with the genomic profiling of a patient's cancerous tumour, using either tissue from the tumour, or circulating DNA from a blood test, where no tissue is available.
 
·          This process identifies mutations specific to the individual's cancer. 
 
·      Next, RCM uses an intelligent computational system - which utilizes proprietary algorithms - to review more than 4.5 million combinations of commonly used drugs, as well as all newly approved cancer treatments.
 



This computational analysis generates a score which reflects the degree to which a therapy or combination of therapies matches a patient's bio-marker cancer profile.
 Case Study:                                
Lana is a 54 year old resident of Northern Manitoba. She was diagnosed with ovarian cancer 3 years ago. She has had several types of chemo with a poor response. She retained Rupert Case Management to organize her molecular profiling. We organized a blood test. The lab analysis of her circulating DNA shed by the tumour into her bloodstream indicated that she had 5 driver mutations. 

Three of the mutations were associated with actionable strategies. RCM sent her molecular profiling report plus her clinical records for computational analysis. That analysis showed the probability of success with 3 drug combinations, 2 drug combinations and mono-therapy (one drug therapy). The analysis showed high probabilities for the combinations and zero probability of success with the drugs previously used. This was a big insight for the treating team. This is proving to be the future for decision support for cancer using big data. This advanced approach is available at RCM today.
 The Breakthrough of Computational Analysis:
                                
The intelligent analysis allows potential mono-therapies, two-drug combinations, and three-drug combinations to be scored and ranked to target specific molecular aberration of the patient's cancer.
 
Rupert Case Management is pleased to be using this world class intelligent computing platform to assist our clients and their treating Oncologists with the complex decisions about the design of personalized treatments for cancer.
TO START THE CONVERSATION:                                               
To learn more -  call, click or email.

1-800-620-7551 or 647-350-5500
 
 
 
It all starts with a conversation.   We are always pleased to help.
 

           



           Raymond Rupert MD. MBA.
           Founder/Medical Director
           Rupert Case Management Inc.
           505 Eglinton Avenue West, Suite 203
           Toronto, ON M5N 1B1
           
newHEADER
Join Our Mailing List
 
View our Previous Newsletters